Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application PCT/US2012/037648, filed May 11, 2012. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,001,610 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof In force · High confidence UsedRemaining | Apellis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 11,661,441 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof In force · High confidence | Apellis Pharmaceuticals, Inc. | In force | High confidence | ||
| US 10,125,171 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof In force · High confidence | Apellis Pharmaceuticals, Inc. | In force | High confidence | ||
| Application 18/133,372 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof Abandoned Abandoned Sep 29, 2025 | Apellis Pharmaceuticals, Inc. | Abandoned | Abandoned Sep 29, 2025 | ||
| Application 19/197,537 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof Pending Not granted | Apellis Pharmaceuticals, Inc. | Pending | Not granted | ||
| Application 19/229,679 | Cell-Reactive, Long-Acting, or Targeted Compstatin Analogs and Uses Thereof Pending Not granted | Apellis Pharmaceuticals, Inc. | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Apellis Pharmaceuticals, Inc..
Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.